$18.63 $0.23 (1.3%)

04:00 PM EST on 11/22/19

Aerie Pharmaceuticals (NASDAQ:AERI)

CAPS Rating: 2 out of 5

Current Price $18.63 Mkt Cap $852.3M
Open $18.40 P/E Ratio 0.00
Prev. Close $18.40 Div. (Yield) $0.00 (0.0%)
Daily Range $18.09 - $18.67 Volume 466,800
52-Wk Range $17.15 - $50.10 Avg. Daily Vol. 1,346,207

Caps

How do you think NASDAQ:AERI will perform against the market?

Add Stock to CAPS Watchlist

All Players

25 Outperform
7 Underperform
 

All-Star Players

5 Outperform
5 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:AERI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

superstar (99.95)
Submitted June 25, 2014

Positive phase 2b trial results for its experimental glaucoma drug, Roclatan

zzlangerhans (99.78)
Submitted February 18, 2016

Aerie's share price was 17.8 when I entered my red thumb, and my start price was 16.75. I won't end up with as many points, but I think I'll still come away with a win. And my real life short entry of 1000 shares at 18.4 isn't subject to the CAPS… More

NASDAQ:AERI VS S&P 500 (SPY)

Fools bullish on NASDAQ:AERI are also bullish on:

Fools bearish on NASDAQ:AERI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AERI.

Recs

0
Member Avatar TMFBlacknGold (94.01) Submitted: 11/22/2019 11:51:34 AM : Outperform Start Price: $20.63 NASDAQ:AERI Score: -13.83

From 10/21/2019:

"Aerie Pharmaceuticals serves as a reminder to investors that reporting positive results in a phase 3 clinical trial, or even earning regulatory approval, means relatively little if commercialization efforts run into obstacles. The sluggish launch of Rhopressa and slow coverage adoption for Rocklatan have combined to push the company's market cap below $1 billion for the first time since 2016.

It may take time to smooth out the paperwork of Medicare D expansion and formulary coverage, but investors shouldn't write off this pharma stock just yet. Flush with cash and positioned to end 2019 on a high note -- assuming bottles sold to pharmacies translates into an increase in prescriptions -- Aerie Pharmaceuticals could find a spot in your portfolio at current levels."

https://www.fool.com/investing/2019/10/21/is-aerie-pharmaceuticals-a-buy.aspx

Leaderboard

Find the members with the highest scoring picks in AERI.

Score Leader

Plasmidologist

Plasmidologist (30.61) Score: +212.88

The Score Leader is the player with the highest score across all their picks in AERI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Tqluu 85.30 9/26/2016 Underperform 5Y $38.52 -51.64% +44.63% +96.26 0 Comment
WildShaman 97.10 7/9/2018 Underperform 5Y $67.75 -72.50% +12.45% +84.95 0 Comment
mavericktrading 99.34 2/19/2014 Underperform 5Y $20.73 -10.13% +68.44% +78.57 0 Comment
portefeuille 98.35 5/1/2015 Outperform 5Y $9.59 +94.26% +48.17% +46.09 0 Comment
MMCapitalMgmt 99.92 8/29/2014 Underperform 5Y $16.81 +10.83% +55.14% +44.31 0 Comment
km00nster < 20 4/24/2015 Underperform 5Y $15.90 +17.17% +46.92% +29.75 0 Comment
Sandygan < 20 5/26/2015 Outperform 5Y $10.99 +69.52% +46.41% +23.11 0 Comment
sikiliza < 20 7/29/2019 Underperform 5Y $22.78 -18.22% +3.01% +21.23 0 Comment
boknows1 64.63 5/13/2015 Outperform 5Y $11.70 +59.23% +47.76% +11.48 0 Comment
gunda7907 < 20 11/20/2019 Outperform 5Y $18.11 +2.87% +0.58% +2.30 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AERI.